OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $34.00 at HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR) had its price target lowered by HC Wainwright from $40.00 to $34.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also issued reports about the company. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Leerink Partners assumed coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. Finally, Oppenheimer cut their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $32.33.

OnKure Therapeutics Price Performance

OKUR opened at $4.91 on Tuesday. The firm has a fifty day simple moving average of $5.60. The stock has a market capitalization of $65.97 million, a price-to-earnings ratio of -0.40 and a beta of 0.28. OnKure Therapeutics has a 12-month low of $4.45 and a 12-month high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, equities analysts expect that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Hedge Funds Weigh In On OnKure Therapeutics

Several hedge funds have recently bought and sold shares of OKUR. Highbridge Capital Management LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $3,438,000. Geode Capital Management LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $659,000. Aisling Capital Management LP acquired a new position in OnKure Therapeutics during the fourth quarter worth $762,000. Aldebaran Capital LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $392,000. Finally, Renaissance Technologies LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $408,000. 90.98% of the stock is owned by institutional investors and hedge funds.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.